Spero Historical Financial Ratios
| SPRO Stock | USD 0.87 0.01 1.16% |
Spero Therapeutics is promptly reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 2.22, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.0896 will help investors to properly organize and evaluate Spero Therapeutics financial condition quickly.
Spero |
About Spero Financial Ratios Analysis
Spero TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Spero Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Spero financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Spero Therapeutics history.
Spero Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Spero Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Spero Therapeutics sales, a figure that is much harder to manipulate than other Spero Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Spero Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Spero Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.At this time, Spero Therapeutics' Current Ratio is very stable compared to the past year. As of the 30th of January 2025, Debt To Equity is likely to grow to 0.08, while Price To Sales Ratio is likely to drop 0.87.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 8.14 | 191.29 | 219.98 | 294.95 | PTB Ratio | 0.86 | 0.72 | 0.83 | 0.79 |
Spero Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Spero Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Spero Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 46.52 | 27.09 | 1.34 | 0.8 | 0.92 | 0.87 | |
| Ptb Ratio | 3.29 | 5.6 | 0.86 | 0.72 | 0.83 | 0.79 | |
| Days Sales Outstanding | 241.61 | 52.8 | 8.14 | 191.29 | 219.98 | 294.95 | |
| Book Value Per Share | 5.9 | 2.86 | 2.02 | 2.03 | 2.33 | 2.22 | |
| Free Cash Flow Yield | (0.43) | (0.29) | (0.2) | (0.12) | (0.38) | (0.4) | |
| Operating Cash Flow Per Share | (3.84) | (2.08) | (0.21) | (0.63) | (0.56) | (0.59) | |
| Capex To Depreciation | 5.96 | 0.42 | 0.21 | 0.0604 | 0.0694 | 0.066 | |
| Pb Ratio | 3.29 | 5.6 | 0.86 | 0.72 | 0.83 | 0.79 | |
| Ev To Sales | 38.23 | 21.33 | (0.77) | 0.0691 | 0.0795 | 0.0755 | |
| Free Cash Flow Per Share | (3.84) | (2.08) | (0.21) | (0.63) | (0.56) | (0.59) | |
| Roic | (0.77) | (0.56) | (0.58) | (0.41) | 0.13 | 0.12 | |
| Inventory Turnover | (3.86) | (4.92) | (5.47) | (0.35) | (0.31) | (0.33) | |
| Net Income Per Share | (3.46) | (2.96) | (1.28) | 0.43 | 0.39 | 0.41 | |
| Days Of Inventory On Hand | (94.53) | (74.19) | (66.67) | (1.1K) | (1.2K) | (1.2K) | |
| Payables Turnover | 58.01 | 1.01 | 2.51 | 0.27 | 0.31 | 0.29 | |
| Sales General And Administrative To Revenue | 2.3 | 2.28 | 0.75 | 0.26 | 0.3 | 0.29 | |
| Research And Ddevelopement To Revenue | 7.18 | 3.53 | 0.98 | 0.53 | 0.61 | 0.58 | |
| Capex To Revenue | 0.61 | 0.0662 | 0.0168 | 0.002136 | 0.002457 | 0.002334 | |
| Cash Per Share | 5.67 | 4.74 | 2.9 | 1.45 | 1.67 | 1.58 | |
| Pocfratio | (5.05) | (7.69) | (8.41) | (2.35) | (2.7) | (2.84) | |
| Capex To Operating Cash Flow | (0.0615) | (0.006277) | (0.001828) | (6.06E-4) | (5.45E-4) | (5.73E-4) | |
| Pfcf Ratio | (5.05) | (7.69) | (8.41) | (2.35) | (2.7) | (2.84) | |
| Days Payables Outstanding | 6.29 | 359.77 | 145.58 | 1.4K | 1.6K | 1.5K | |
| Income Quality | 1.1 | 0.72 | 0.17 | (1.45) | (1.66) | (1.58) | |
| Roe | (0.59) | (1.03) | (0.63) | 0.21 | 0.19 | 0.2 | |
| Ev To Operating Cash Flow | (4.15) | (6.05) | 4.84 | (0.2) | (0.18) | (0.19) | |
| Pe Ratio | (5.6) | (5.42) | (1.35) | 3.4 | 3.06 | 3.21 | |
| Return On Tangible Assets | (0.51) | (0.53) | (0.38) | 0.13 | 0.11 | 0.12 | |
| Ev To Free Cash Flow | (4.15) | (6.06) | 4.84 | (0.2) | (0.18) | (0.19) | |
| Net Debt To E B I T D A | 1.01 | 1.21 | 2.42 | (2.75) | (3.16) | (3.0) | |
| Current Ratio | 8.85 | 8.46 | 5.04 | 3.53 | 3.18 | 4.59 | |
| Tangible Book Value Per Share | 5.9 | 2.86 | 2.02 | 2.03 | 2.33 | 2.22 | |
| Receivables Turnover | 1.51 | 6.91 | 44.81 | 1.91 | 1.72 | 1.63 | |
| Graham Number | 21.44 | 13.78 | 7.62 | 4.44 | 5.11 | 4.85 | |
| Shareholders Equity Per Share | 5.9 | 2.86 | 2.02 | 2.03 | 2.33 | 2.22 | |
| Debt To Equity | 0.0594 | 0.0831 | 0.0875 | 0.0519 | 0.0596 | 0.0783 | |
| Capex Per Share | 0.15 | 0.0173 | 0.007013 | 0.001262 | 0.001452 | 0.001379 |
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Spero Stock
Moving against Spero Stock
| 0.74 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
| 0.43 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.38 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share | Quarterly Revenue Growth 2.754 | Return On Assets |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.